The effects of oral soybean phospholipid on serum total cholesterol, plasma triglyceride, and serum high-density lipoprotein cholesterol concentrations in hyperlipidemia

JPEN J Parenter Enteral Nutr. 1985 Nov-Dec;9(6):716-9. doi: 10.1177/0148607185009006716.

Abstract

In a randomized, double-blind, cross-over trial soybean phospholipid and placebo, 18 g daily for 6 wk, were given orally to 20 patients on long-term treatment with standard lipid lowering diets. The effect of this treatment on serum total cholesterol and high-density lipoprotein cholesterol and plasma triglyceride was studied. After 6 wk mean (+/- SE) cholesterol concentration was decreased by 0.54 (+/- 0.19) mmol/liter in phospholipid-treated as compared to placebo-treated patients (p less than 0.02). The decrease in serum cholesterol was significant (p less than 0.02) only in patients assigned to receive phospholipid before placebo. A highly significant increase (p less than 0.001) followed the withdrawal of phospholipid. No effect on triglyceride and high-density lipoprotein cholesterol concentrations was demonstrated.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Body Weight
  • Cholesterol / blood*
  • Cholesterol, HDL / blood*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Food, Fortified
  • Glycine max*
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / diet therapy*
  • Male
  • Middle Aged
  • Phospholipids / administration & dosage*
  • Random Allocation
  • Triglycerides / blood*

Substances

  • Cholesterol, HDL
  • Phospholipids
  • Triglycerides
  • Cholesterol